SCHEMBL1476244

SCHEMBL1476244

O=C(O)CC1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL288786 1.00
SCHEMBL288677 1.00
Hydrochloric Acid SCHEMBL17223559 0.98 FDPS (0.43)
Hydrochloric Acid SCHEMBL2035544 0.98 FDPS (0.43)
Bromide SCHEMBL9376271 0.98 FDPS (0.43)
Hydrochloric Acid SCHEMBL4060601 0.98 FDPS (0.43)
Bromide SCHEMBL9376277 0.98 FDPS (0.43)
Hydrochloric Acid SCHEMBL643019 0.98 FDPS (0.43)
Hydrochloric Acid SCHEMBL22800513 0.96 FDPS (0.42)
SCHEMBL644279 0.93 FDPS (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 884 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 US claimed
US-20260015393-A1 NOVEL NMU RECEPTOR 2 AGONISTS BOEHRINGER INGELHEIM INT (DE) 2026-01-15 US claimed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 US claimed
EP-4028494-B1 REDUCING FRICTION IN COMBUSTION ENGINES THROUGH FUEL ADDITIVES CHEVRON ORONITE CO (US) 2025-08-06 EP claimed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 CN claimed
EP-4554607-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-05-21 EP claimed
CN-119075601-A Organic amine composition, carbon dioxide absorbent and application thereof 国家能源集团新能源技术研究院有限公司 2024-12-06 CN claimed
WO-2024015880-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS, INC. (US) 2024-01-18 WO claimed
EP-4029513-A1 MELANOCORTIN-4 RECEPTOR AGONISTS FOR THE TREATMENT OF DISORDERS CHARACTERISED BY POMC GENE HYPERMETHYLATION Rhythm Pharmaceuticals, Inc. (US) 2022-07-20 EP claimed
CN-113307851-B Application of active peptide and mesenchymal stem cell exosome for improving skin physiological characteristics in medicines or cosmetics 珠海医美企业管理有限公司 2022-04-29 CN claimed
US-20220127305-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2022-04-28 US claimed
US-20180118721-A1 PYRIMIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2018-05-03 US claimed
EP-3256132-A1 PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER Merck Patent GmbH (DE) 2017-12-20 EP claimed
CN-107207482-A Pyrimidine derivatives for treating cancer 默克专利股份公司 2017-09-26 CN claimed
CN-106832027-A The extracting method of gumbo polysaccharide 浙江海洋大学 2017-06-13 CN claimed
WO-2016128140-A1 PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER MERCK PATENT GMBH (DE) 2016-08-18 WO claimed
CN-101052609-A Synthesis of 1,5-distributed-2-hydroxy-Gibbatetraen-6-ones MERCK & CO INC (US) 2007-10-10 CN claimed
JP-4208286-A None JP disclosed
US-4217238-A BASIC SALT, SCRUBBING EXXON RESEARCH & ENGINEERING CO. (US) 1980-08-12 US disclosed
US-4094957-A CARBON DIOXIDE EXXON RESEARCH & ENGINEERING CO. (US) 1978-06-13 US disclosed